End-Stage Renal Failure Clinical Trial
Official title:
A Local Pilot Evaluation of Laboratory Monitoring of Renal Patients on Erythropoietin and /or Iron Therapy Using Mean Reticulated Haemoglobin Equivalent (RetHe) and Their Response to Therapy
NCT number | NCT01126905 |
Other study ID # | 2010FAL1 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2010 |
Est. completion date | October 7, 2010 |
Verified date | November 2018 |
Source | University of Ulster |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Anaemia is a common complication of Chronic Kidney Disease (CKD) the management of which has
been aided by the use of synthetic recombinant human erythropoietin therapy (r-HuEPO). This
red cell stimulating agent creates the further complication of Functional Iron Deficiency
(FID) where, despite normal iron stores, patients fail to respond to therapy as they do not
possess enough available iron to meet the demand of increased red cell production. Effective
response to r-HuEPO therapy depends on an appropriate monitoring of 'available' iron levels.
Previous research into the clinical utility of testing for reticulated haemoglobin
concentrations (Ret He) instead of Serum Ferritin and Transferrin Saturation analysis has
indicated an advantage as an iron deficient prognostic marker however, further knowledge is
required on the use of this new laboratory test (RetHe) to predict Functional Iron Deficiency
(FID) level and to study it's relationship with responses to therapy.
This proposed study aims to estimate a local working Normal (non deficient) and Iron
Deficient Reticulated Haemoglobin Content (RET He) reference range from surplus anonamous
samples. Routine monthly blood samples from Pre Dialysis and Haemodialysis patients will be
used to evaluate the sensitivity and specificity of the RET He test compared to current
laboratory tests and investigate its predictive ability for Functional Iron Deficiency in
these patients.
Studying , measuring and statistically analysing the change in the RET He parameters in
Haemodialysis and Pre Dialysis patients over 3 months will look for evidence of a direct
relationship between RET He values and the patients response to therapy. The data will be
used to provide a predictive picture of what levels of RET He indicate Functional Iron
Deficiency.
The introduction of this test (RetHe) may provide clinicians with a one sample/one test
control over iron therapies and ensure the patient gets the most benefit from erythropoietin
therapy.
Status | Completed |
Enrollment | 250 |
Est. completion date | October 7, 2010 |
Est. primary completion date | October 7, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Two groups of random routine anonamised blood samples (for use in determinimg a local normal range for the Reticulated Haemoglobin Content [RetHe])will be included in the study: Normal red blood cell (RBC) Indices (Hb , Haematocrit, Mean Cell Volume ande Mean Cell Haemoglobin Content) ; an attempt will be made to select an equal mixture of men / women and an appropriate age spread to provide a valid control range for the group of test subjects (renal patients) The student Investigator will ask Haematology staff to record minimum details of iron deficient patients and "normal" test results noted at routine validation [positive identification number (barcode)/ age / sex] - these samples will be coded and additionally analysed for RetHe test. Exclusion Criteria: - All renal patient who have had surgery and / or a Blood Transfusion OR bleeding episodes within the last month prior to the study are excluded as this would interfere with red cell parameters. All patients < 16 years and >85 years are excluded from the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Ulster | NHS Fife |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01449266 -
Safety and Dialysability of Dotarem® in Dialysed Patients
|
Phase 1 | |
Completed |
NCT01656135 -
Reference Group Trial for The ONE Study
|
Phase 4 | |
Completed |
NCT00807144 -
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
|
Phase 4 | |
Active, not recruiting |
NCT00238043 -
Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia
|
Phase 3 | |
Completed |
NCT02129881 -
The ONE Study UK Treg Trial
|
Phase 1/Phase 2 | |
Completed |
NCT01687699 -
Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients
|
Phase 4 |